Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 24 (1) , 607-619
Abstract
Nivolumab has been approved for advanced squamous and non-squamous non-small cell lung cancer (NSCLC) following platinum-based chemotherapy in both Canada and Sweden. We aimed to determine the valu...Keywords
Funding Information
- Bristol Myers Squibb
This publication has 21 references indexed in Scilit:
- FDA Approves Opdivo for Non-Squamous NSCLCOncology Times, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Swedish experience-based value sets for EQ-5D health statesQuality of Life Research, 2013
- Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World SettingJournal of Thoracic Oncology, 2013
- Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemiaThe European Journal of Health Economics, 2012
- Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation StudiesPLOS ONE, 2012
- Health State Utility Scores for Cancer-Related Anemia through Societal and Patient ValuationsValue in Health, 2008
- Health state utilities for non small cell lung cancerHealth and Quality of Life Outcomes, 2008